Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2.
immunology
virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
24 Sep 2021
24 Sep 2021
Historique:
received:
20
03
2021
revised:
27
06
2021
accepted:
30
07
2021
pubmed:
10
8
2021
medline:
10
8
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety, and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T-cell-mediated immunity. Hamsters immunized with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.
Identifiants
pubmed: 34368648
doi: 10.1016/j.isci.2021.102941
pii: S2589-0042(21)00909-3
pmc: PMC8332743
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102941Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI161175
Pays : United States
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Cancer Res. 2004 Nov 1;64(21):8057-61
pubmed: 15520216
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
J Virol. 2005 Nov;79(21):13275-84
pubmed: 16227250
J Med Virol. 2020 Jul;92(7):909-914
pubmed: 32222992
Vaccine. 1997 Apr;15(5):533-40
pubmed: 9160521
J Infect Dis. 2010 Oct 1;202(7):1011-20
pubmed: 20715930
Bioeng Bugs. 2011 Jan-Feb;2(1):58-62
pubmed: 21636990
J Virol. 2011 Aug;85(16):8241-52
pubmed: 21632762
J Virol Methods. 2021 Jan;287:113995
pubmed: 33068703
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
J Clin Oncol. 2002 May 1;20(9):2251-66
pubmed: 11980996
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105
pubmed: 32475066
EBioMedicine. 2020 Dec;62:103132
pubmed: 33232870
Am J Obstet Gynecol. 2020 Jul;223(1):131-134
pubmed: 32376320
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Open Biol. 2020 Sep;10(9):200160
pubmed: 32961074
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Vaccines (Basel). 2020 Mar 03;8(1):
pubmed: 32138253
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Commun. 2016 Sep 01;7:12651
pubmed: 27582256
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Clin Cancer Res. 1996 Jan;2(1):21-8
pubmed: 9816085
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Vaccines (Basel). 2020 Dec 17;8(4):
pubmed: 33348607
Curr Opin Mol Ther. 2008 Feb;10(1):46-55
pubmed: 18228181
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Vaccine. 2010 Apr 19;28(18):3159-70
pubmed: 20189484
Vaccine. 2010 Jun 17;28(27):4394-401
pubmed: 20434545
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Virology. 2020 Sep;548:39-48
pubmed: 32838945
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
J Virol. 2010 Feb;84(3):1489-503
pubmed: 19923177
J Clin Microbiol. 2004 Jan;42(1):329-38
pubmed: 14715773
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Front Immunol. 2019 Jul 17;10:1605
pubmed: 31379823
Protein Cell. 2015 Jul;6(7):480-503
pubmed: 25944045
Sci Rep. 2016 Sep 06;6:32973
pubmed: 27596047
Nat Rev Immunol. 2012 Jul 25;12(8):592-605
pubmed: 22828912
Cell. 2020 Oct 1;183(1):169-184.e13
pubmed: 32931734
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Infect Chemother. 2020 Jun;52(2):154-164
pubmed: 32537961
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
Vaccine. 2010 Dec 10;29(1):17-25
pubmed: 21034822
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Sci Rep. 2019 Apr 2;9(1):5520
pubmed: 30940854
Virology. 2008 Aug 1;377(2):255-64
pubmed: 18570964
J Virol. 2009 Jan;83(2):584-97
pubmed: 19004953
Virology. 2012 Oct 25;432(2):327-35
pubmed: 22726244
J Virol. 2000 Dec;74(24):11626-35
pubmed: 11090161
Hum Vaccin Immunother. 2018 Jul 3;14(7):1717-1733
pubmed: 29624470
JAMA. 2020 Jul 21;324(3):294-296
pubmed: 32511676
Vaccines (Basel). 2020 Aug 24;8(3):
pubmed: 32846910
Hum Vaccin Immunother. 2013 Sep;9(9):1962-70
pubmed: 23896606
J Virol. 2007 Jan;81(1):150-8
pubmed: 17050610